Published on : Mar 01, 2017
Albany, New York, March 1, 2017: From the past few years, it has been analyzed that the increasing number of HIV patients are shown to be a highly probable factor to develop cryptococcosis during late-stage HIV infection. Due to this, the demand for cryptococcosis treatment is growing. Market Research Hub (MRH) has recently added the latest report which examines the current and future scenario of the global market and titled as “Global Industry Analysis Cryptococcosis Market” 2016-2024 Forecast. The study describes that one of the key factors driving the global cryptococcosis market is the increasing incidence of cryptococcosis infections across the world. The researchers further find that the global market is projected to reach US$6.27 billion by 2024, after growing at a CAGR of 4.8% from the period 2016 to 2024.
Initially, the report describes the market overview of Cryptococcosis along with its segmentation and competitive landscape. Cryptococcosis is disease due to a species of the fungus Cryptococcus. C. neoformans which typically infects immunocompromised persons.
In the next section, the report also delivers information and data analysis of the global market with respect to the segments based on treatment, distribution channel and geography. Geographically, the market has been segmented into five major regions including North America, Asia-Pacific, Europe, MEA and Latin America. According to the market analysts, the disease burden is rising in recent years due to the upsurge in vulnerable patient population such as HIV-infected patients, solid organ transplantation recipients and other immunosuppressive hosts.
Based on distribution channel, the global cryptococcosis market is segmented into hospital pharmacies, retail pharmacies, drug store and mail order pharmacies. Among these, retail pharmacy is expected to continue to dominate the market by 2024. By treatment, the market is segmented into
- Amphotericin B
- Fluconazole and other antifungals
Furthermore, the report also includes a major viewpoint of ‘Centers for Disease Control and Prevention’ (CDC) which has estimated that around 1 million cryptococcal meningitis cases occur globally. Most people in the United States who develop cryptococcal infections are HIV-positive. Also, it is also seen that cryptococcosis mortality burden is very high which results in around 625,000 deaths every year.
In terms of geography, the research findings display that The North American region is projected to continue to dominate the global cryptococcosis market till 2024, due to the rising incidence of the infection in endemic areas of the U.S. and higher penetration of healthcare services across the country. Additionally, the cryptococcosis market in the Middle East and Africa is also projected to expand at a substantial growth rate owing to the impact of Sub-Sahara African countries in terms of demand, where the count of HIV patients is extremely high.
Click here to get more info with TOC in a PDF Format:http://www.marketresearchhub.com/enquiry.php?type=S&repid=981634
At last, major players profiled in this report include Bristol-Myers Squibb Company, Valeant Pharmaceuticals, Inc., Abbott Laboratories, Novartis AG, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Glenmark Pharmaceuticals and Sigmapharm Laboratories LLC.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com